Cargando…
Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721523/ https://www.ncbi.nlm.nih.gov/pubmed/31382518 http://dx.doi.org/10.3390/cells8080817 |
_version_ | 1783448362791469056 |
---|---|
author | Roda, Giulia Porru, Emanuele Katsanos, Konstantinos Skamnelos, Alexandros Kyriakidi, Kallirroi Fiorino, Gionata Christodoulou, Dimitrios Danese, Silvio Roda, Aldo |
author_facet | Roda, Giulia Porru, Emanuele Katsanos, Konstantinos Skamnelos, Alexandros Kyriakidi, Kallirroi Fiorino, Gionata Christodoulou, Dimitrios Danese, Silvio Roda, Aldo |
author_sort | Roda, Giulia |
collection | PubMed |
description | Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes under anti-TNF alpha treatment. Methods: Forty CD and 40 UC patients were enrolled and BAs were quantified by high-pressure liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ES-MS/MS). Up to 15 different sBAs concentrations and clinical biomarkers where added to a Principal Component Analysis (PCA) to discriminate IBD from healthy conditions and treatment. Results: PCA allowed a separation into two clusters within CD (biologic-free patients and patients treated with anti-TNF alpha drugs and healthy subjects) but not UC. The first included CD. CD patients receiving anti-TNF alpha have an increase in total sBAs (4.11 ± 1.23 μM) compared to patients not exposed. Secondary BAs significantly increase after anti-TNF alpha treatment (1.54 ± 0.83 μM). Furthermore, multivariate analysis based on sBA concentration highlighted a different qualitative sBAs profile for UC and CD patients treated with conventional therapy. Conclusion: According to our results, anti-TNF alpha in CD restores the sBA profile by re-establishing the physiological levels. These findings indicate that, secondary BAs might serve as an indirect biomarker of the healing process. |
format | Online Article Text |
id | pubmed-6721523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67215232019-09-10 Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs Roda, Giulia Porru, Emanuele Katsanos, Konstantinos Skamnelos, Alexandros Kyriakidi, Kallirroi Fiorino, Gionata Christodoulou, Dimitrios Danese, Silvio Roda, Aldo Cells Article Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes under anti-TNF alpha treatment. Methods: Forty CD and 40 UC patients were enrolled and BAs were quantified by high-pressure liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ES-MS/MS). Up to 15 different sBAs concentrations and clinical biomarkers where added to a Principal Component Analysis (PCA) to discriminate IBD from healthy conditions and treatment. Results: PCA allowed a separation into two clusters within CD (biologic-free patients and patients treated with anti-TNF alpha drugs and healthy subjects) but not UC. The first included CD. CD patients receiving anti-TNF alpha have an increase in total sBAs (4.11 ± 1.23 μM) compared to patients not exposed. Secondary BAs significantly increase after anti-TNF alpha treatment (1.54 ± 0.83 μM). Furthermore, multivariate analysis based on sBA concentration highlighted a different qualitative sBAs profile for UC and CD patients treated with conventional therapy. Conclusion: According to our results, anti-TNF alpha in CD restores the sBA profile by re-establishing the physiological levels. These findings indicate that, secondary BAs might serve as an indirect biomarker of the healing process. MDPI 2019-08-02 /pmc/articles/PMC6721523/ /pubmed/31382518 http://dx.doi.org/10.3390/cells8080817 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Roda, Giulia Porru, Emanuele Katsanos, Konstantinos Skamnelos, Alexandros Kyriakidi, Kallirroi Fiorino, Gionata Christodoulou, Dimitrios Danese, Silvio Roda, Aldo Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs |
title | Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs |
title_full | Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs |
title_fullStr | Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs |
title_full_unstemmed | Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs |
title_short | Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs |
title_sort | serum bile acids profiling in inflammatory bowel disease patients treated with anti-tnfs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721523/ https://www.ncbi.nlm.nih.gov/pubmed/31382518 http://dx.doi.org/10.3390/cells8080817 |
work_keys_str_mv | AT rodagiulia serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT porruemanuele serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT katsanoskonstantinos serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT skamnelosalexandros serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT kyriakidikallirroi serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT fiorinogionata serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT christodouloudimitrios serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT danesesilvio serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs AT rodaaldo serumbileacidsprofilingininflammatoryboweldiseasepatientstreatedwithantitnfs |